Shilpa Medicare gets USFDA nod for cancer treatment injection

NEW DELHI: Shilpa Medicare Tuesday said it has received approval from the US health regulator for Irinotecan HCL injection, used for treatment of certain kind of cancers.

The company has received US Food and Drug Administration (USFDA) approval for its ANDA Irinotecan HCL injection USP in the strengths 40 mg/2mL and 100 mg/5mL (20mg/mL) single dose vials, Shilpa Medicare said in a BSE filing.

Irinotecan injection is used in the treatment of patients with metastatic carcinoma of the colon or rectum, the company added.

Quoting IQVIA MAT second quarter 2018 data, Shilpa Medicare said the US market for Irinotecan HCL is approximately USD 18 million.

Shares of Shilpa Medicare were trading 3.80 per cent up at Rs 398.65 apiece on BSE.

  • Related Posts

    Meiji Seika to push new vaccine with SII in India

    TOKYO: Meiji Seika Pharma-owned Medreich Pharma is eyeing inorganic growth and more generics supply from India, while the parent has tied up with Serum Institute of India (SII) to launch…

    DGFT automates EO extension process to ease compliance for pharma exporters

    Mumbai: The Directorate General of Foreign Trade (DGFT) has introduced an automated facility for granting Export Obligation (EO) extensions in Advance Authorisation and Export Promotion Capital Goods (EPCG) Authorisation cases…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Meiji Seika to push new vaccine with SII in India

    Meiji Seika to push new vaccine with SII in India

    DGFT automates EO extension process to ease compliance for pharma exporters

    DGFT automates EO extension process to ease compliance for pharma exporters

    Udan vs Udaan: Delhi court restrains pharmaceutical firm from using ‘Udaan’ mark

    Udan vs Udaan: Delhi court restrains pharmaceutical firm from using ‘Udaan’ mark

    Three newborns die in fire at government hospital in Amravati, Maharashtra

    Three newborns die in fire at government hospital in Amravati, Maharashtra

    Maharashtra FDA to prioritise process audits for revised Schedule M compliance: FDA Commissioner

    Maharashtra FDA to prioritise process audits for revised Schedule M compliance: FDA Commissioner

    Centre bans fixed-dose combination for Common Cold in children below four

    Centre bans fixed-dose combination for Common Cold in children below four